ashwagandha vs berberine

Can You Take Ashwagandha and Berberine Together? What Studies Show

Quick answer. We found no study that tested ashwagandha and berberine together, so whether the pair is safe or adds anything is unknown. We found no published report of a harmful reaction between them, but their cautions overlap: both may lower blood sugar, both should be avoided in pregnancy and breastfeeding, and both can upset the stomach. Most trials of each were short and measured different outcomes: stress, anxiety and sleep scores for ashwagandha, blood sugar and cholesterol for berberine. The main safety point is medicines: berberine slows several drug-processing enzymes, and ashwagandha has been linked to rare liver injury and thyroid changes, so ask a doctor or pharmacist first if you take diabetes, blood pressure, thyroid, sedative or transplant medicines.

Ashwagandha vs berberine at a glance

Ashwagandha Berberine
What it is Withania somnifera, an evergreen shrub, also called winter cherry or Indian ginseng, though it does not belong to the ginseng family A single plant compound, an isoquinoline alkaloid, found in goldenseal, barberry (Berberis) and other plants
Part or form Most supplements use root extracts; some use root and leaf, which differ in chemistry Purified berberine in capsules or tablets; little of a swallowed dose reaches the blood
Main compounds Withanolides (steroidal lactones) and other plant chemicals Berberine itself
What human trials tested Stress and anxiety scales, sleep, cortisol, mostly in trials of 6 to 12 weeks Blood sugar and blood lipids, mostly in people with type 2 diabetes or high lipids; most lipid trials ran in China
Typical study amounts 240 to 1,250 mg of extract a day in stress trials; 120 to 600 mg in sleep trials 0.6 to 1.0 g a day in divided doses in the trials cited here
Main safety points Rare liver injury; thyroid hormone changes; avoid in pregnancy and breastfeeding; possible interactions with several medicine groups Stomach upset; slows CYP2D6, CYP2C9 and CYP3A4; raised cyclosporine levels; avoid in pregnancy, breastfeeding and infants
Regulatory notes Illegal to sell in Denmark (NIH ODS dates the ban to 2023); France's food safety agency advised several groups against it in April 2024; a Dutch restriction is proposed, not final A January 2026 European Food Safety Authority draft (not final as of October 25, 2026) found no safe intake can currently be established

For a full review of berberine trials, see our berberine evidence review.

What the research says about taking them together

No combined study. On October 25, 2026, PubMed held 15 records mentioning both ashwagandha (or Withania somnifera) and berberine; none tested the two together in people. ClinicalTrials.gov listed 86 ashwagandha studies and 127 berberine studies, none including both.

Where their effects and cautions overlap.

  • Blood sugar. In placebo-controlled trials, berberine lowered fasting blood sugar by about 9 mg/dL and ashwagandha by about 3 mg/dL (very low certainty). The NIH's National Center for Complementary and Integrative Health (NCCIH) lists diabetes medicines among possible ashwagandha interactions; France's food safety agency (ANSES) lists low blood sugar as a berberine risk.
  • Blood pressure. NCCIH lists blood pressure medicines among possible ashwagandha interactions; ANSES lists low blood pressure as a berberine risk.
  • Sedatives and drug levels. NCCIH lists sedatives and anti-seizure medicines among possible ashwagandha interactions, and ANSES advises people taking sedatives not to use ashwagandha supplements. Separately, berberine raised exposure to the sedative midazolam by 40% in healthy men.
  • Liver and heart conditions. ANSES advises people with liver or heart disorders against both ashwagandha and berberine supplements.
  • Stomach. Digestive complaints, such as nausea or loose stools, are among the most common side effects of both.
  • Pregnancy and breastfeeding. NCCIH advises against both.

What human studies have tested

Study Who took part Form and daily amount Duration What was measured Result
Akhgarjand et al., 2022 (meta-analysis of randomized trials) 12 trials, 1,002 adults aged 25 to 48 Ashwagandha extracts, doses varied Varied Anxiety and stress scores Lower anxiety (SMD −1.55) and stress (SMD −1.75) than placebo; high heterogeneity; certainty of evidence rated low
Albalawi, 2025 (meta-analysis of randomized trials) 7 trials on cortisol, 6 on perceived stress; 488 participants At least 250 mg a day At least 2 weeks Blood cortisol; Perceived Stress Scale Cortisol −1.16 µg/dL; no significant difference in perceived stress
Cheah et al., 2021 (meta-analysis of randomized trials) 5 trials, 400 adults, all in India, with or without insomnia 4 trials used a root extract, 1 a root-and-leaf extract; 120 to 600 mg 6 to 12 weeks Sleep quality and quantity Small improvement in overall sleep (SMD −0.59), larger in insomnia, at 600 mg or more and at 8 weeks or longer; 1 trial partly sponsored by a manufacturer
Farrin et al., 2026 (meta-analysis of randomized trials) 11 trials, 667 participants Ashwagandha, doses varied Varied Fasting blood sugar, HbA1c Fasting sugar −3.09 mg/dL; HbA1c result inconclusive (3 trials); certainty very low
Sharma et al., 2018 (randomized, double-blind pilot; India) 50 adults with subclinical hypothyroidism (46 completed) Ashwagandha root extract, 600 mg 8 weeks Thyroid hormones TSH fell and T3 and T4 rose compared with placebo
Zhao et al., 2023 (meta-analysis of placebo-controlled trials) 20 trials, 1,761 adults with and without diabetes Berberine, doses varied Varied Fasting blood sugar, HbA1c Fasting sugar −0.52 mmol/L (about −9 mg/dL); HbA1c −4.48 mmol/mol (about −0.4 percentage points); larger fasting-sugar drops in people with diabetes (subgroup finding)
Blais et al., 2023 (meta-analysis of placebo-controlled trials) 18 trials, 1,788 adults; 15 in mainland China or Hong Kong Berberine, doses varied 4 to 24 weeks Blood lipids; side effects LDL −0.46 mmol/L (about −18 mg/dL); triglycerides −0.34 mmol/L; digestive side effects 2–23% vs 2–15% with placebo
Lei et al., 2026 (randomized, double-blind; 11 hospitals in China) 337 adults with obesity and fatty liver, without diabetes Berberine 1 g 6 months Belly fat and liver fat by CT scan No difference in belly fat or liver fat; LDL 7.7 mg/dL lower than placebo (secondary result); similar side effects
Guo et al., 2012 (randomized crossover; China) 17 healthy young men Berberine 300 mg three times a day (900 mg) 14 days Activity of drug-processing enzymes Lower CYP2D6, CYP2C9 and CYP3A4 activity; midazolam exposure (AUC) up 40%
Wu et al., 2005 (randomized controlled; China) 104 kidney transplant recipients taking cyclosporine, plus 6 in a drug-level study Berberine 0.2 g three times a day (600 mg) 3 months Cyclosporine blood levels Final cyclosporine levels 29% higher than in patients not taking berberine
Any study of both together None found — — — —

What the findings suggest. Ashwagandha trials show lower stress and anxiety scores and slightly better sleep than placebo, but trials were short and small, with low certainty for stress and anxiety. Results are mixed: one meta-analysis found lower cortisol but no change in perceived stress, and NCCIH calls the anxiety evidence "unclear." Berberine trials show modest drops in blood sugar and blood lipids, mostly in people with type 2 diabetes or high lipids.

Practical points the evidence supports

  • Timing. We found no study comparing taking them together, apart or at different times of day.
  • What the trials did. Ashwagandha trials mostly lasted about 1 to 3 months; the berberine trials cited here gave it in divided doses, for example 300 mg three times a day. These are study facts, not recommendations; follow your product label.
  • Medicine check. If you take medicine for diabetes, blood pressure, thyroid disease, seizures, anxiety or sleep, or to prevent transplant rejection, ask your doctor or pharmacist first, including whether you need extra blood sugar checks.

Safety

Liver. NIH LiverTox rates ashwagandha a likely cause of clinically apparent liver injury. It usually appeared 2 to 12 weeks after starting, with jaundice and itching, and resolved within 1 to 4 months of stopping. Rare deaths or emergency transplants have been reported, especially in people with existing liver disease; in an Indian series of 8 cases, all 3 who presented with acute-on-chronic liver failure died. LiverTox says berberine has not been linked to published cases of clinically apparent liver injury.

Thyroid. In 50 adults with subclinical hypothyroidism, ashwagandha root extract raised T3 and T4 and lowered TSH compared with placebo; a 2026 meta-analysis of 23 trials found a modest rise in T4 but no change in TSH or T3. NIH's Office of Dietary Supplements (ODS) notes three case reports of thyrotoxicosis (excess thyroid hormone) in women and says ashwagandha might interact with thyroid hormone medicines. NCCIH does not recommend it for people with thyroid or autoimmune disorders.

Medicines. In 17 healthy men, berberine (900 mg a day for 2 weeks) lowered the activity of CYP2D6, CYP2C9 and CYP3A4, enzymes that process many drugs, and in kidney transplant recipients it left cyclosporine levels 29% higher than without it. In rats, berberine raised levels of oral digoxin and cyclosporine, which the authors linked to blocking P-glycoprotein, a pump that moves many drugs out of cells; we found no human study of berberine with digoxin. For ashwagandha, we found no human study that measured medicine levels. Lab studies are mixed: one found no reversible inhibition of 7 drug-processing enzymes; another found an ethanol root extract changed CYP3A4 activity in cultured human liver cells. A Polish review of 2021–2022 drug-safety reports linked ashwagandha taken with antidepressants to 7 adverse events, such as severe diarrhea, which the authors attributed to possible interactions.

Blood sugar. A meta-analysis of berberine trials in type 2 diabetes, some combined with diabetes drugs, found no significant rise in low blood sugar. Even so, ANSES advises people with diabetes to avoid berberine supplements.

Pregnancy, breastfeeding and infants. NCCIH says ashwagandha "should be avoided during pregnancy and should not be used while breastfeeding." It also says people who are pregnant or breastfeeding "should not use berberine, and it should not be given to infants," because berberine can cause or worsen jaundice in newborns.

Other groups. NCCIH does not recommend ashwagandha before surgery and advises people with hormone-sensitive prostate cancer to avoid it, because it may raise testosterone. ANSES also advises children and adolescents to avoid berberine supplements.

Side effects and duration. ODS calls ashwagandha's common side effects (stomach upset, loose stools, nausea, drowsiness) mild and says it appears well tolerated for up to about 3 months; long-term safety is unknown. NCCIH lists abdominal pain, constipation, diarrhea, nausea and vomiting as berberine's most common side effects.

Regulators. The FDA does not approve dietary supplements for safety or effectiveness. Denmark's food agency states that selling ashwagandha products is illegal there, after a 2020 risk assessment found no safe intake of the root could be set; ODS dates the ban to 2023. In April 2024, ANSES advised pregnant women and people with thyroid disorders, among others, not to use ashwagandha supplements, and, as a precaution, breastfeeding women and children. A Dutch draft rule restricting ashwagandha went to public consultation in early 2025; we found no final rule as of October 25, 2026. For berberine, a January 2026 European Food Safety Authority draft opinion concluded that "no safe intake can currently be established," citing a possible DNA-damage signal in lab tests; we found no final opinion as of October 25, 2026. We found no official upper limit for either.

What research does not establish

  • That taking ashwagandha and berberine together is safe, or that the pair works better than either alone.
  • Whether either changes blood levels of the other.
  • That ashwagandha changes blood levels of any medicine in people.
  • Long-term safety of either beyond a few months.
  • That either one treats anxiety, insomnia, diabetes or high cholesterol.

How we reviewed the evidence

On October 25, 2026, we searched PubMed for records mentioning both ingredients (15 records), ashwagandha meta-analyses and systematic reviews (57), ashwagandha drug-interaction and drug-level studies (69 and 104 records in two searches) and berberine P-glycoprotein studies (17), screened all by title or abstract, and searched ClinicalTrials.gov. We read four key papers in full and the rest as abstracts, checked cited papers against PubMed's retraction listings, and read official pages from NIH ODS, NCCIH, LiverTox, ANSES, EFSA, the FDA and the Danish and Dutch governments. Lab and animal studies were used only for mechanisms. Vinatura did not run any trials.

Vinatura Research Perspective

We asked whether anyone has studied the pair, where the known effects of each overlap, and whether the studies of each measure comparable things. First, we found no trial, case report or registered study of the combination. The earlier version of this page said no direct contraindications had been reported; that reflects an absence of studies, not evidence of safety, and it did not mention the shared cautions on blood sugar, pregnancy and medicines. It also framed the pair as covering different body systems, stress for one and metabolism for the other; we found no study of whether combining them does anything.

Second, the two evidence bases answer different questions: berberine trials mostly measured lab values such as HbA1c and LDL, while ashwagandha trials mostly measured self-rated stress, anxiety and sleep. A "vs" comparison is therefore a comparison of goals, not of strength. Third, forms and data differ: 4 of 5 sleep trials used a root extract, ODS notes that root and leaf differ in chemistry, and some products use both. Berberine has human drug-level studies; for ashwagandha we found only lab studies and adverse-event reports.

Our assessment: no evidence on the combination; low-certainty evidence that ashwagandha lowers stress and anxiety scores in short trials, with small sleep improvements; modest, fairly consistent glucose and lipid effects for berberine in people with type 2 diabetes or high lipids; and safety signals that overlap on blood sugar and medicines. A placebo-controlled trial of the two together measuring blood sugar, thyroid and liver tests, or a human drug-level study of ashwagandha, would change this assessment.

Where these ingredients appear in Vinatura products

DihydroBerberine with Ceylon Cinnamon contains 250 mg dihydroberberine (GlucoVantage®) and 250 mg Ceylon cinnamon (Cinnamomum verum) per capsule, 1 capsule per serving, 30 capsules. Dihydroberberine is a related compound, not berberine itself; see our dihydroberberine review. Cortisol Balance Pro lists 2 capsules per serving (30 servings); each serving includes 250 mg ashwagandha (Withania somnifera root and leaf extract), along with rhodiola, L-theanine, phosphatidylserine, vitamins C and B6 and other ingredients listed on the product page. The studies above did not test these products.

Frequently asked questions

Can you take berberine with ashwagandha? We found no study of the combination, so its safety is unknown. Their cautions overlap on blood sugar, pregnancy and medicines, so ask a doctor or pharmacist first.

Berberine vs ashwagandha: which is better? They were studied for different things: berberine for blood sugar and cholesterol, ashwagandha for stress, anxiety and sleep scores. We found no trial comparing them directly.

Can I take ashwagandha and berberine at the same time? We found no study of timing for the pair. Follow each product's label.

Can I take them with metformin or thyroid medicine? Ask your prescriber first. Both lowered blood sugar in trials, ashwagandha has changed thyroid hormone levels, and berberine slows several drug-processing enzymes.


References

  • Akhgarjand C, et al. Does ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(11):4115–4124. doi:10.1002/ptr.7598
  • Albalawi AA. Dual impact of ashwagandha: significant cortisol reduction but no effects on perceived stress. A systematic review and meta-analysis. Nutr Health. 2025;31(4):1395–1408. doi:10.1177/02601060251363647
  • Cheah KL, et al. Effect of ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One. 2021;16(9):e0257843. doi:10.1371/journal.pone.0257843
  • Farrin N, et al. The effects of ashwagandha (Withania somnifera) supplementation on fasting blood glucose and HbA1c: a systematic review and dose-response meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2026;241:113529. doi:10.1016/j.diabres.2026.113529
  • Sharma AK, Basu I, Singh S. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. J Altern Complement Med. 2018;24(3):243–248. doi:10.1089/acm.2017.0183
  • Fornalik M, et al. Hormonal modulation with Withania somnifera: systematic review and meta-analysis of randomized-controlled trials. Planta Med. 2026;92(8):790–805. doi:10.1055/a-2802-8363
  • Philips CA, et al. Ashwagandha-induced liver injury: a case series from India and literature review. Hepatol Commun. 2023;7(10):e0270. doi:10.1097/HC9.0000000000000270
  • Raichura Z, et al. Evaluation of reversible cytochrome P450 inhibition by Withania somnifera leaf and root extracts. Drug Metab Dispos. 2025;53(2):100024. doi:10.1016/j.dmd.2024.100024
  • McDonald KL, et al. Ashwagandha (Withania somnifera) plant extracts affect the cytochrome P450 system and cytotoxicity of primary human hepatocytes. J Diet Suppl. 2025;22(4):613–639. doi:10.1080/19390211.2025.2514458
  • Siwek M, Woroń J, Wrzosek A, Gupało J, Chrobak AA. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs. Front Pharmacol. 2023;14:1271776. doi:10.3389/fphar.2023.1271776
  • Zhao JV, et al. Overall and sex-specific effect of berberine on glycemic and insulin-related traits: a systematic review and meta-analysis of randomized controlled trials. J Nutr. 2023;153(10):2939–2950. doi:10.1016/j.tjnut.2023.08.016
  • Blais JE, Huang X, Zhao JV. Overall and sex-specific effect of berberine for the treatment of dyslipidemia in adults: a systematic review and meta-analysis of randomized placebo-controlled trials. Drugs. 2023;83(5):403–427. doi:10.1007/s40265-023-01841-4
  • Xie W, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045. doi:10.3389/fphar.2022.1015045
  • Lei L, et al. Berberine and adiposity in diabetes-free individuals with obesity and MASLD: a randomized clinical trial. JAMA Netw Open. 2026;9(1):e2554152. doi:10.1001/jamanetworkopen.2025.54152
  • Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213–217. doi:10.1007/s00228-011-1108-2
  • Wu X, et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567–572. doi:10.1007/s00228-005-0952-3
  • Qiu W, et al. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res. 2009;23(11):1553–1558. doi:10.1002/ptr.2808
  • Blöcher JA, et al. Sex-dependent effects of CYP2D6 on the pharmacokinetics of berberine in humans. Clin Pharmacol Ther. 2025;117(1):250–260. doi:10.1002/cpt.3454
  • NIH Office of Dietary Supplements. Ashwagandha: Is it helpful for stress, anxiety, or sleep? Fact sheet for health professionals. Updated May 2, 2025. ods.od.nih.gov
  • National Center for Complementary and Integrative Health (NCCIH). Ashwagandha: Usefulness and Safety. Last updated March 2023. nccih.nih.gov
  • National Center for Complementary and Integrative Health (NCCIH). In the News: Berberine. Last updated June 2023. nccih.nih.gov
  • National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Ashwagandha. Last updated December 3, 2024. ncbi.nlm.nih.gov
  • National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Berberine. Last updated October 6, 2020. ncbi.nlm.nih.gov
  • ANSES (French Agency for Food, Environmental and Occupational Health & Safety). Use of berberine-containing plants in food supplements. November 25, 2019. anses.fr
  • EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Draft scientific opinion on the safety of plant preparations containing berberine (EFSA-Q-2022-00803). Endorsed January 29, 2026. connect.efsa.europa.eu
  • ANSES. Avis relatif aux risques liés à l'utilisation des préparations de Withania somnifera (L.) Dunal dans les compléments alimentaires (saisine 2021-SA-0077). April 19, 2024. anses.fr
  • ANSES. Nutrivigilance: rapport d'activité 2024. Accessed October 25, 2026. anses.fr
  • Danish Veterinary and Food Administration (Fødevarestyrelsen). Ashwagandha i kosttilskud og drikkevarer. Accessed October 25, 2026. foedevarestyrelsen.dk
  • DTU National Food Institute. Risikovurdering: Withania somnifera (note to Fødevarestyrelsen). May 15, 2020. foedevarestyrelsen.dk
  • Ministry of Health, Welfare and Sport (Netherlands). Wijziging van Warenwetregelgeving in verband met de aanwijzing van schadelijke stoffen in voedingssupplementen en kruidenpreparaten: draft regulation (internet consultation, closed March 24, 2025). Accessed October 25, 2026. internetconsultatie.nl
  • U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Content current as of June 2, 2022. fda.gov

Editorial note: This article reviews published research for educational purposes. It does not establish the effects or safety of any specific supplement, including Vinatura products, and is not medical advice. Written by Vinatura Editorial Team. Last reviewed October 2026.

Author

Vinatura Editorial Team
Vinatura Editorial Team
The Vinatura Editorial Team includes our founders, researchers, and content writers. We review published studies and trusted health sources first, then write from that evidence, aiming to be clear and balanced about what the research does and does not show. Selected articles are also reviewed by one of our medical reviewers. When an article has been reviewed, the reviewer's name appears on that article. Vinatura Supplements sells dietary supplements, so some articles discuss ingredients we use or compare our products with others. Our articles are for education and are not medical advice.
Disclaimers (Expand to read all):

Agreement

By accessing and reading the articles or blogs on this website, you acknowledge and agree to the terms of these disclaimers. These disclaimers are subject to change without notice.

Medical Disclaimer

The information provided in the articles on this website is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.

Product Disclaimer

Including an ingredient or study does not evaluate, endorse, or recommend any Vinatura product or any third-party product. Some ingredients discussed may not be used in any Vinatura product.

The content of the articles has not been evaluated by the Food and Drug Administration (FDA) and is not intended to promote or endorse any specific product. Any products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.

Opinions and Endorsements

Any claims, statements, or opinions expressed in the articles are those of the author(s) and do not necessarily reflect the views or opinions of the manufacturers of the dietary supplement products. The products sold on this website are separate from the content of the articles and are not directly endorsed or associated with the information presented here.

Liability Disclaimer

The author(s) of the articles, website, and manufacturers of the dietary supplement products do not assume any liability for any potential consequences arising from the use of the information provided in the articles. Ingredient effects, dosages, and safety vary by individual, formulation, and context; some ingredients interact with medications or may be unsuitable during pregnancy or lactation. It is recommended that individuals consult with a qualified healthcare professional before making any dietary or lifestyle changes, including the use of dietary supplements.

Product Usage

Please refer to the product labels and packaging for specific usage instructions and guidelines for the dietary supplement products sold on this website.

Customer Support

For any concerns or questions regarding the dietary supplement products, please contact our customer support team, who will be more than happy to assist you.

Leave a Comment

0 Comments

Be the first to comment.

What do you think?

Please note, comments need to be approved before they are published.
Table of Contents
Show All

Articles

Bowl of dry soybeans, a dish of golden lecithin granules, walnuts and reading glasses on a notebook on a wooden table

Phosphatidylserine: What Research Shows on Memory and Stress

Quick answer. Phosphatidylserine (PS) is a phospholipid, a fat-like building block of cell membranes
0 comments
Dish of black activated charcoal powder with charcoal granules, a beaker of water with settling black powder, a stirring rod and pipette

Activated Charcoal: What Research Shows, From Poisoning to Dail

Quick answer. Activated charcoal is a fine, highly porous carbon that holds many drugs
0 comments
Red Vine Leaf Benefits: What the AS 195 Extract Trials Show

Red Vine Leaf Benefits: What the AS 195 Extract Trials Show

Quick answer. Red vine leaf is the dried leaf of red-leaved grapevines (Vitis vinifera),
0 comments